vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and PRECISION BIOSCIENCES INC (DTIL). Click either name above to swap in a different company.

PRECISION BIOSCIENCES INC is the larger business by last-quarter revenue ($34.2M vs $19.2M, roughly 1.8× CuriosityStream Inc.). PRECISION BIOSCIENCES INC runs the higher net margin — 58.9% vs -19.7%, a 78.6% gap on every dollar of revenue. On growth, PRECISION BIOSCIENCES INC posted the faster year-over-year revenue change (5261.1% vs 35.8%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-11.3M). Over the past eight quarters, PRECISION BIOSCIENCES INC's revenue compounded faster (39.5% CAGR vs 26.5%).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

CURI vs DTIL — Head-to-Head

Bigger by revenue
DTIL
DTIL
1.8× larger
DTIL
$34.2M
$19.2M
CURI
Growing faster (revenue YoY)
DTIL
DTIL
+5225.3% gap
DTIL
5261.1%
35.8%
CURI
Higher net margin
DTIL
DTIL
78.6% more per $
DTIL
58.9%
-19.7%
CURI
More free cash flow
CURI
CURI
$15.2M more FCF
CURI
$3.9M
$-11.3M
DTIL
Faster 2-yr revenue CAGR
DTIL
DTIL
Annualised
DTIL
39.5%
26.5%
CURI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CURI
CURI
DTIL
DTIL
Revenue
$19.2M
$34.2M
Net Profit
$-3.8M
$20.1M
Gross Margin
Operating Margin
-17.6%
36.6%
Net Margin
-19.7%
58.9%
Revenue YoY
35.8%
5261.1%
Net Profit YoY
-34.6%
213.5%
EPS (diluted)
$-0.07
$2.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
DTIL
DTIL
Q4 25
$19.2M
$34.2M
Q3 25
$18.4M
$13.0K
Q2 25
$19.0M
$18.0K
Q1 25
$15.1M
$29.0K
Q4 24
$14.1M
$638.0K
Q3 24
$12.6M
$576.0K
Q2 24
$12.4M
$49.9M
Q1 24
$12.0M
$17.6M
Net Profit
CURI
CURI
DTIL
DTIL
Q4 25
$-3.8M
$20.1M
Q3 25
$-3.7M
$-21.8M
Q2 25
$784.0K
$-23.5M
Q1 25
$319.0K
$-20.6M
Q4 24
$-2.8M
Q3 24
$-3.1M
$-16.4M
Q2 24
$-2.0M
$32.7M
Q1 24
$-5.0M
$8.6M
Operating Margin
CURI
CURI
DTIL
DTIL
Q4 25
-17.6%
36.6%
Q3 25
-24.5%
-158976.9%
Q2 25
2.5%
-121538.9%
Q1 25
0.5%
-76248.3%
Q4 24
-27.4%
Q3 24
-25.8%
-3693.6%
Q2 24
-20.6%
48.4%
Q1 24
-30.4%
-23.8%
Net Margin
CURI
CURI
DTIL
DTIL
Q4 25
-19.7%
58.9%
Q3 25
-20.4%
-167476.9%
Q2 25
4.1%
-130666.7%
Q1 25
2.1%
-70913.8%
Q4 24
-19.9%
Q3 24
-24.3%
-2851.6%
Q2 24
-16.4%
65.6%
Q1 24
-42.0%
48.8%
EPS (diluted)
CURI
CURI
DTIL
DTIL
Q4 25
$-0.07
$2.62
Q3 25
$-0.06
$-1.84
Q2 25
$0.01
$-2.13
Q1 25
$0.01
$-2.21
Q4 24
$-0.05
Q3 24
$-0.06
$-2.25
Q2 24
$-0.04
$4.67
Q1 24
$-0.09
$1.70

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
DTIL
DTIL
Cash + ST InvestmentsLiquidity on hand
$27.3M
$115.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.5M
$92.2M
Total Assets
$75.7M
$154.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
DTIL
DTIL
Q4 25
$27.3M
$115.6M
Q3 25
$27.8M
$44.9M
Q2 25
$28.1M
$62.2M
Q1 25
$33.4M
$77.2M
Q4 24
$32.1M
$86.3M
Q3 24
$33.2M
$101.2M
Q2 24
$39.5M
$123.6M
Q1 24
$38.8M
$137.8M
Stockholders' Equity
CURI
CURI
DTIL
DTIL
Q4 25
$41.5M
$92.2M
Q3 25
$47.2M
$16.6M
Q2 25
$49.8M
$34.1M
Q1 25
$58.1M
$49.3M
Q4 24
$57.8M
$56.4M
Q3 24
$62.2M
$64.9M
Q2 24
$64.8M
$74.7M
Q1 24
$67.0M
$37.2M
Total Assets
CURI
CURI
DTIL
DTIL
Q4 25
$75.7M
$154.4M
Q3 25
$74.7M
$93.5M
Q2 25
$78.7M
$108.9M
Q1 25
$85.3M
$124.4M
Q4 24
$86.2M
$136.4M
Q3 24
$87.6M
$153.3M
Q2 24
$90.9M
$165.8M
Q1 24
$94.6M
$184.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
DTIL
DTIL
Operating Cash FlowLast quarter
$4.0M
$-11.3M
Free Cash FlowOCF − Capex
$3.9M
$-11.3M
FCF MarginFCF / Revenue
20.5%
-32.9%
Capex IntensityCapex / Revenue
0.1%
0.1%
Cash ConversionOCF / Net Profit
-0.56×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
DTIL
DTIL
Q4 25
$4.0M
$-11.3M
Q3 25
$4.4M
$-15.3M
Q2 25
$2.8M
$-20.3M
Q1 25
$1.9M
$-19.1M
Q4 24
$3.0M
$-58.4M
Q3 24
$2.3M
$-5.9M
Q2 24
$2.2M
$-14.9M
Q1 24
$666.0K
$-19.0M
Free Cash Flow
CURI
CURI
DTIL
DTIL
Q4 25
$3.9M
$-11.3M
Q3 25
Q2 25
$-20.3M
Q1 25
$1.8M
$-19.1M
Q4 24
$-58.7M
Q3 24
$-6.0M
Q2 24
$-14.9M
Q1 24
$-19.1M
FCF Margin
CURI
CURI
DTIL
DTIL
Q4 25
20.5%
-32.9%
Q3 25
Q2 25
-112627.8%
Q1 25
12.2%
-65917.2%
Q4 24
-9199.8%
Q3 24
-1033.2%
Q2 24
-29.9%
Q1 24
-108.4%
Capex Intensity
CURI
CURI
DTIL
DTIL
Q4 25
0.1%
0.1%
Q3 25
0.0%
0.0%
Q2 25
0.0%
11.1%
Q1 25
0.5%
220.7%
Q4 24
0.0%
39.2%
Q3 24
0.0%
6.8%
Q2 24
0.0%
0.1%
Q1 24
0.0%
0.5%
Cash Conversion
CURI
CURI
DTIL
DTIL
Q4 25
-0.56×
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
-0.45×
Q1 24
-2.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons